Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases


Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.blueprintmedicines.com

Recent News

March 5, 2019
Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference

February 26, 2019
Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results

February 19, 2019
Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

Read More News

Associated Team Members

Alexis Borisy
Partner